• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by MannKind Corporation

    4/1/25 5:02:02 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNKD alert in real time by email
    DEFA14A 1 mnkd_defa_14a_2025.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    (RULE 14a-101)

    INFORMATION REQUIRED IN

    PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒

     

     

    Filed by a Party other than the Registrant  ☐

    Check the appropriate box:

     ☐

    ​

    ​

    Preliminary Proxy Statement

     ☐

    ​

    ​

    Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    ​

    ​

    Definitive Proxy Statement

     ☒

    ​

    ​

    Definitive Additional Materials

     ☐

    ​

    ​

    Soliciting Material Pursuant to § 240.14a-12

     

    MANNKIND CORPORATION

    (Name of Registrant as Specified in its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

     

     

    Payment of Filing Fee (Check all boxes that apply):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


     

     

    Your Vote Counts! MANNKIND CORPORATION 2024 Annual Meeting Vote by May 14, 2024 11:59 PM ET Company Logo 1 CASPER STREET DANBURY, CT 06810 V45604-P05211 You invested in MANNKIND CORPORATION and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 15, 2024. Get informed before you vote View the Annual Report and Notice and Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 1, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote Virtually at the Meeting* May 15, 2024 10:00 AM EDT Virtually at: www.virtualshareholdermeeting.com/MNKD2024 For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* May 15, 2024 10:00 AM EDT Virtually at: www.virtualshareholdermeeting.com/MNKD2024 *Please check the meeting materials for any special requirements for meeting attendance.img107523360_0.jpg


     

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1.To elect the nine nominees named herein as directors to serve for the ensuing year and img107523360_1.jpguntil their successors are elected; Nominees: 01)James S. Shannon, M.D., MRCP (UK)06) Anthony Hooper02) Michael E. Castagna, Pharm.D.07) Sabrina Kay, Ed.D.03) Ronald J. Consiglio08) Kent Kresa04) Michael A. Friedman, M.D.09) Christine Mundkur05) Jennifer Grancio For 2.To approve, on an advisory basis, the compensation of the named executive officers of MannKind, as disclosed in MannKind’s proxy statement for the Annual Meeting; For 3.To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of MannKind for its fiscal year ending December 31, 2024; and For 4. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V45605-P05211


    Get the next $MNKD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNKD

    DatePrice TargetRatingAnalyst
    4/10/2025$12.00Outperform
    Mizuho
    2/10/2025$11.00Outperform
    Wedbush
    12/20/2024$9.00Overweight
    Wells Fargo
    12/19/2024$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    9/9/2024$7.00 → $8.00Outperform
    Leerink Partners
    6/13/2024$8.00Buy
    Rodman & Renshaw
    10/10/2023$10.00Outperform
    Wedbush
    2/28/2022$6.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $MNKD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

      DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase inhaled insulin at the American Diabetes Association's (ADA) 85th Scientific Sessions from June 20-23 in Chicago. Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will present the results from the randomized period of the INHALE-1 clinical trial during a "Future Ready" symposium. Dr. Haller is the Chair for MannKind's Phase 3 INHALE-1 study of A

      6/9/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

      WESTLAKE VILLAGE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) for a one-of-a-kind experience with Detroit area youth and families during the week of the Chevrolet Detroit Grand Prix in downtown Detroit. Daly will share his personal story of being diagnosed with diabetes as a teen and how he does not let it keep him from living life without limits. The former karting champion will also provide some karting tips and then race go-karts to identify the Fastest 6. Daly was first diagnosed with diabetes at the age of 14, and today is the only known U.S. professional r

      5/27/25 9:15:00 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind to Present at Upcoming Investor Conferences

      DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind's Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences, both being held in New York City: RBC Capital Markets 2025 Global Annual Healthcare Conference Tuesday, May 20, 8:00 a.m. ET Jefferies Global Healthcare Conference Thursday, June 5,

      5/13/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    SEC Filings

    See more
    • MannKind Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - MANNKIND CORP (0000899460) (Filer)

      5/19/25 5:02:22 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by MannKind Corporation

      8-K - MANNKIND CORP (0000899460) (Filer)

      5/15/25 4:08:08 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by MannKind Corporation

      144 - MANNKIND CORP (0000899460) (Subject)

      5/13/25 4:02:55 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Mannkind with a new price target

      Mizuho initiated coverage of Mannkind with a rating of Outperform and set a new price target of $12.00

      4/10/25 12:42:30 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Mannkind with a new price target

      Wedbush initiated coverage of Mannkind with a rating of Outperform and set a new price target of $11.00

      2/10/25 7:01:41 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Mannkind with a new price target

      Wells Fargo initiated coverage of Mannkind with a rating of Overweight and set a new price target of $9.00

      12/20/24 7:44:06 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Pres, Endocrine Business Unit Marasco Dominic

      4 - MANNKIND CORP (0000899460) (Issuer)

      6/25/25 9:00:08 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Binder Steven B. sold $256,340 worth of shares (64,085 units at $4.00), decreasing direct ownership by 6% to 925,258 units (SEC Form 4)

      4 - MANNKIND CORP (0000899460) (Issuer)

      6/10/25 8:07:37 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP Chief Medical Officer Blank Burkhard covered exercise/tax liability with 15,630 shares, decreasing direct ownership by 3% to 465,124 units (SEC Form 4)

      4 - MANNKIND CORP (0000899460) (Issuer)

      5/27/25 7:26:54 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Leadership Updates

    Live Leadership Updates

    See more
    • MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

      MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

      1/5/22 6:05:00 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care